Establishment and characterization of a novel breast implant-associated anaplastic large cell lymphoma cell line and PDX model (BIA-XR1) with a unique KRAS mutation

IF 3.2 4区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL

Current Research in Translational Medicine Pub Date : 2023-07-01 DOI:10.1016/j.retram.2023.103401

Ioanna Xagoraris , Konstantina Stathopoulou , Roberta D' Aulerio , Minghui He , Anett Ketscher , Kenbugul Jatta , Felix Haglund de Flon , Gisela Barbany , Richard Rosenquist , Lisa S. Westerberg , George Z. Rassidakis

{"title":"Establishment and characterization of a novel breast implant-associated anaplastic large cell lymphoma cell line and PDX model (BIA-XR1) with a unique KRAS mutation","authors":"Ioanna Xagoraris , Konstantina Stathopoulou , Roberta D' Aulerio , Minghui He , Anett Ketscher , Kenbugul Jatta , Felix Haglund de Flon , Gisela Barbany , Richard Rosenquist , Lisa S. Westerberg , George Z. Rassidakis","doi":"10.1016/j.retram.2023.103401","DOIUrl":null,"url":null,"abstract":"<div><p>Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon T-cell lymphoma type with distinct clinical, molecular and genetic features. Establishment of BIA-ALCL cell lines and patient-derived xenograft (PDX) models are essential experimental tools to investigate the molecular pathogenesis of the disease. We characterized a novel BIA-ALCL cell line and PDX model, named BIA-XR1, derived from a patient with textured breast implant who developed lymphoma. Next-generation sequencing revealed a <em>STAT3</em> mutation, commonly detected in BIA-ALCL, and a unique <em>KRAS</em> mutation reported for the first time in this lymphoma type. Both JAK/STAT3 and RAS/MEK/ERK oncogenic pathways were activated in BIA-XR1, which are targetable with clinically available agents.</p></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"71 3","pages":"Article 103401"},"PeriodicalIF":3.2000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Research in Translational Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2452318623000259","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon T-cell lymphoma type with distinct clinical, molecular and genetic features. Establishment of BIA-ALCL cell lines and patient-derived xenograft (PDX) models are essential experimental tools to investigate the molecular pathogenesis of the disease. We characterized a novel BIA-ALCL cell line and PDX model, named BIA-XR1, derived from a patient with textured breast implant who developed lymphoma. Next-generation sequencing revealed a STAT3 mutation, commonly detected in BIA-ALCL, and a unique KRAS mutation reported for the first time in this lymphoma type. Both JAK/STAT3 and RAS/MEK/ERK oncogenic pathways were activated in BIA-XR1, which are targetable with clinically available agents.

查看原文本刊更多论文

具有独特KRAS突变的新型乳腺植入物相关间变性大细胞淋巴瘤细胞系和PDX模型（BIA-XR1）的建立和表征。

乳房植入物相关间变性大细胞淋巴瘤（BIA-ALCL）是一种罕见的T细胞淋巴瘤，具有独特的临床、分子和遗传特征。建立BIA-ALCL细胞系和患者来源的异种移植物（PDX）模型是研究该疾病分子发病机制的重要实验工具。我们鉴定了一种新的BIA-ALCL细胞系和PDX模型，命名为BIA-XR1，来源于一名患有淋巴瘤的有纹理乳房植入物的患者。下一代测序揭示了一种STAT3突变，通常在BIA-ALCL中检测到，以及首次在该淋巴瘤类型中报道的一种独特的KRAS突变。JAK/STAT3和RAS/MEK/ERK致癌途径均在BIA-XR1中被激活，其可被临床可用的药物靶向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Research in Translational Medicine Biochemistry, Genetics and Molecular Biology-General Biochemistry,Genetics and Molecular Biology

CiteScore

7.00

自引率

4.90%

发文量

审稿时长

45 days

期刊介绍： Current Research in Translational Medicine is a peer-reviewed journal, publishing worldwide clinical and basic research in the field of hematology, immunology, infectiology, hematopoietic cell transplantation, and cellular and gene therapy. The journal considers for publication English-language editorials, original articles, reviews, and short reports including case-reports. Contributions are intended to draw attention to experimental medicine and translational research. Current Research in Translational Medicine periodically publishes thematic issues and is indexed in all major international databases (2017 Impact Factor is 1.9). Core areas covered in Current Research in Translational Medicine are: Hematology, Immunology, Infectiology, Hematopoietic, Cell Transplantation, Cellular and Gene Therapy.